HOME >> BIOLOGY >> NEWS
New screening method turns up potential compound for treating anthrax

University of Chicago scientists have identified a compound that halts the activity of a deadly toxin called anthrax lethal factor in laboratory tests. Nature Biotechnology will publish the findings online on May 16 and in the June issue of the journal's print edition.

Anthrax lethal factor can only be effectively treated with antibiotics if administered soon after infection, making it difficult to treat patients who were unknowingly exposed to the bacterium. The Chicago research aims to develop a drug that could treat anthrax after antibiotics become ineffective.

The Chicago team discovered that a compound called DS-998 showed promising activity against anthrax lethal factor in cell cultures. Lethal factor is a molecule that chops up and renders inactive a protein that helps cells stay healthy. DS-998 blocks lethal factor's harmful cutting action.

The Chicago research is also the first time application of mass spectrometry to screen a library of compounds for medical applications. "We screened 10,000 compounds in three days. We estimate that it would be possible to screen 50,000 compounds a day with available robotic equipment," said Milan Mrksich, Professor in Chemistry at the University of Chicago. His co-authors of the Nature Biotechnology article are Dal-Hee Min, a Ph.D. student in chemistry, and Wei-Jen Tang, Associate Professor in the Ben May Institute for Cancer Research, both at the University of Chicago,

Rapid screening is an important component in making drug development more economical. It can cost a pharmaceutical company $250 million to develop a drug. Research and development alone can exceed $25 million, Mrksich said. "Typically hundreds of thousands of molecules are screened to identify 10 that are candidate drug leads," he said.

The search focused on small-molecule compounds. "In order to prevent the action of these toxins you need to have a molecule that is easily penetrable into the cell
'"/>

Contact: Steve Koppes
skoppes@uchicago.edu
773-702-8366
University of Chicago
16-May-2004


Page: 1 2

Related biology news :

1. March of Dimes statement on newborn screening report
2. Only 21 states offer newborn screening tests recommended by March of Dimes
3. Genetic screening study at Stanford IDs most aggressive adult leukemia strains
4. Genetic screening recommended to detect new neurodegenerative disorder in men over age 50
5. HPV testing could be future strategy for primary screening for cervical cancer
6. Newborn screening for certain genetic disorders has benefits and some drawbacks
7. SARS pre-screening protocol developed for AACR Annual Meeting in Washington, D.C.
8. UNC HIV-AIDS screening, prevention method could become national model for cutting illness
9. Study boosts confidence in potential screening tool for Alzheimers disease
10. Study: Prenatal screening in Haiti region cut syphilis by 75 percent
11. Study may help explain sunlights role in melanoma development, have screening implications

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2020)... ... February 14, 2020 , ... ... that include integrated eTMF and Payment tracking, will be showcasing SimpleTrials at the ... , Since attending the SCOPE Summit last year, the SimpleTrials team has completed ...
(Date:2/11/2020)... ... February 11, 2020 , ... Modality Solutions, ... its ISO 9001:2015 registration by certification body Intertek. Modality Solutions’ Quality Manager, Hannah ... revised all existing Standard Operating Procedures (SOPs) and created ten new SOPs. Anderson ...
(Date:2/6/2020)... ... February 06, 2020 , ... Syntactx, ... device and pharmaceutical trials, announced that Ms. Dorothy Abel has joined the ... oversees the development and execution of regulatory plans designed to help clients ...
Breaking Biology News(10 mins):
(Date:1/23/2020)... ... , ... Ideal Implant CEO and President Robert S Hamas, ... American investor forums specializing in medical advancements. New technology was presented to US ... November 21, 2019 in New York City, and the Aesthetic Technology Summit in ...
(Date:1/22/2020)... ... January 21, 2020 , ... QCDx , a private biotech company ... blood draw, today announced the sale of the proprietary RareScope™ instrument to the Carole ... used in clinical cancer research. , “The RareScope can detect and isolate intact and ...
(Date:1/8/2020)... ... 08, 2020 , ... Anomet Products has introduced ... use in harsh environments inside or outside of the human body. , ... alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or operation at temperatures ...
(Date:1/7/2020)... and SOMERVILLE, Mass. (PRWEB) , ... January 06, ... ... Murrow Center for a Digital World at The Fletcher School at Tufts University, ... Alfred P. Sloan Foundation. The grant will be administered by Tufts University, and ...
Breaking Biology Technology:
Cached News: